Discovery of phenylpyrrolidine derivatives as a novel class of retinol binding protein 4 (RBP4) reducers

[Display omitted] Retinol-binding protein 4 (RBP4) is a potential drug target for metabolic and ophthalmologic diseases. A high-throughput screening of our compound library has identified a small-molecule RBP4 reducer 7a, as a hit compound. Aiming to provide a suitable tool for investigating the pha...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2022-01, Vol.54, p.116553-116553, Article 116553
Main Authors: Nakamura, Shinji, Kamaura, Masahiro, Akao, Yuichiro, Nakamura, Natsuko, Mizukami, Atsushi, Goto, Akihiko, Furuyama, Naoki, Cho, Nobuo, Kasai, Shizuo
Format: Article
Language:English
Subjects:
Age-related macular degeneration (AMD)
Diabetes
Dose-Response Relationship, Drug
Drug Discovery
Humans
Molecular Structure
Protein–protein interaction (PPI)
Pyrrolidines - chemical synthesis
Pyrrolidines - chemistry
Pyrrolidines - pharmacology
Retinol-binding protein 4 (RBP4)
Retinol-Binding Proteins, Plasma - antagonists & inhibitors
Retinol-Binding Proteins, Plasma - metabolism
Structure-Activity Relationship
Transthyretin (TTR)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Retinol-binding protein 4 (RBP4) is a potential drug target for metabolic and ophthalmologic diseases. A high-throughput screening of our compound library has identified a small-molecule RBP4 reducer 7a, as a hit compound. Aiming to provide a suitable tool for investigating the pharmacological effects of RBP4 reducers, we conducted a structure–activity relationship study of 7a. Exploration of the aryl head, oxazole core, and propanoic acid tail of 7a resulted in the discovery of novel, potent, and orally available phenylpyrrolidine derivatives 43b and 43c. Compound 43b had a potent and long-lasting blood RBP4-level-reducing effect when orally administered to mice at a dose as low as 0.3 mg/kg.
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2021.116553